Completed PHASE4 INTERVENTIONAL 1-arm NCT00095810

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease

Sponsor: Otsuka America Pharmaceutical

Conditions Parkinson's Disease Psychoses

Interventions aripiprazole

Updated 6 times since 2017 Last updated: Nov 7, 2013 Started: Jul 31, 2003 Primary completion: Sep 30, 2004 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00095810, this PHASE4 trial focuses on Parkinson's Disease and Psychoses and remains completed. Sponsored by Otsuka America Pharmaceutical, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka America Pharmaceutical
Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Albany, United States